Developing the Clinic Market and Large Facilities
First written in FY2016. 18 of 26 entries say "Restated". Latest entry: 2026-11-11.
26 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In the clinical testing business, we sought to strengthen new customer acquisition and expand business performance by optimizing selling prices and conducting in-depth sales activities such as expanding sales of new and priority testing items to existing users. As a result, revenue from the clinical testing business increased 5.1% from the previous fiscal year.」
Progress was indicated in the form of higher revenue in the clinical testing business, with price optimization added to stronger new customer acquisition and expansion of tests among existing users. - 2026-05-13RestatedResults
「「売上・シェア拡大」においては、営業リソースをマーケットに応じ適正に配備するとともに本部ソリューション機能を強化し、お客様の課題解決に取り組むことで取引の拡大を推進します。」
市場に応じた営業リソース配置、本部ソリューション機能の強化、顧客課題解決による取引拡大の方針を再掲している。 - FY2026-H1AdvancedAnnual report
「In the clinical testing business, we sought to strengthen new customer acquisition and expand business performance by optimizing selling prices and conducting in-depth sales activities such as expanding sales of new and priority testing items to existing users. As a result, revenue from the clinical testing business increased 6.1% year on year.」
In addition to strengthening new customer acquisition and expanding tests among existing users, we advanced selling-price optimization, and the clinical testing business recorded a 6.1% year-on-year increase in revenue. - FY2025RestatedAnnual report
「In the clinical testing business, we worked to strengthen new customer acquisition and expand business performance by pursuing in-depth sales to existing users, including the expansion of new and priority tests, and optimizing selling prices.」
We continue the sales policy of acquiring new customers, expanding tests among existing users and optimizing selling prices. - FY2024ReframedAnnual report
「We will appropriately allocate sales resources according to market conditions and strengthen the solutions functions at headquarters, expanding business with customers by addressing their challenges. We will also expand testing items and functions to establish an operating structure that meets customer needs.」
The sales policy has been made more specific, shifting from conventional customer-segment-based development to the allocation of sales resources according to market conditions, headquarters solutions functions and a focus on resolving customer challenges. - FY2024-Q3RestatedAnnual report
「In the clinical testing business, we worked to acquire new customers and expand business performance by pursuing in-depth sales to existing users, including the expansion of new, proprietary and priority tests.」
We continue to acquire new customers and pursue in-depth sales to existing users by expanding new, proprietary and priority tests. - FY2024-Q2RestatedAnnual report
「In the clinical testing business, we worked to acquire new customers and expand business performance by pursuing in-depth sales to existing users, including the expansion of new, proprietary and priority tests.」
We continue to acquire new customers and pursue in-depth sales to existing users by expanding new, proprietary and priority tests. - FY2024-Q1RestatedAnnual report
「In the clinical testing business, we worked to acquire new customers and expand business performance by pursuing in-depth sales to existing users, including the expansion of new, proprietary and priority tests.」
We continue to acquire new customers and pursue in-depth sales to existing users by expanding new, proprietary and priority tests. - FY2023-Q3RestatedAnnual report
「In the clinical testing business, we worked to acquire new customers and expand business performance by pursuing in-depth sales to existing users, including the expansion of new, proprietary and priority tests.」
We continue to acquire new customers and pursue in-depth sales to existing users by expanding new, proprietary and priority tests. - FY2023-Q2RestatedAnnual report
「In the clinical testing business, we worked to acquire new customers and expand business performance by pursuing in-depth sales to existing users, including the expansion of new, proprietary and priority tests.」
We continue to acquire new customers and pursue in-depth sales to existing users by expanding new, proprietary and priority tests. - FY2020-Q2RestatedAnnual report
「In the clinical testing business, we worked to acquire new customers and pursued in-depth sales, including the expansion of new, proprietary and priority tests, in an effort to expand business performance.」
We continue to strengthen new customer acquisition and pursue in-depth sales to existing users by expanding new, proprietary and priority tests. - FY2020-Q1AdvancedAnnual report
「In the clinical testing business, we worked to acquire new customers and pursued in-depth sales, including the expansion of new, proprietary and priority tests, in an effort to expand business performance.」
The company explicitly identified the expansion of new, proprietary and priority tests in customer development and in-depth sales to existing customers. - FY2019RestatedAnnual report
「In the clinical testing business, despite the effects of natural disasters and the small number of operating days, we worked to strengthen new customer acquisition and pursued in-depth sales to existing users, including the expansion of priority tests, in an effort to expand business performance.」
We continue to strengthen new customer acquisition and expand sales of priority tests to existing users. - FY2019-Q3RestatedAnnual report
「In the clinical testing business, although we were affected by natural disasters and the low number of operating days, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of priority testing items to existing users to expand business performance. As a result, revenue from the clinical testing business increased 2.6% year on year.」
The traditional sales policy, including customer development among hospitals and clinics, is being continued in the form of stronger new customer acquisition and in-depth sales to existing users. - FY2019-Q2RestatedAnnual report
「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of priority testing items to existing users to expand business performance. As a result, revenue from the clinical testing business increased 1.3% year on year.」
We continue to strengthen new customer acquisition and pursue in-depth sales to existing users. - FY2019-Q1RestatedAnnual report
「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of priority testing items to existing users to expand business performance. As a result, revenue from the clinical testing business increased 2.7% year on year.」
We continue to strengthen new customer acquisition and pursue in-depth sales to existing users. - FY2018-Q3RestatedAnnual report
「In the clinical testing business, we strengthened coordination between our laboratories and headquarters, sought to develop the hospital and clinic markets, pursued solution-based sales to large facilities, conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and implemented a laboratory utilization strategy using regional and separate laboratories to expand business performance. As a result, revenue from the clinical testing business increased 2.0% year on year.」
We continue sales initiatives targeting the hospital and clinic markets, large facilities and existing users. - FY2018-Q2RestatedAnnual report
「In the clinical testing business, we strengthened coordination between our operating sites and headquarters, sought to develop the hospital and clinic markets, and expanded our business through proposal-based sales using the FMS/branch laboratory model for large facilities, in-depth sales to existing users, including the expansion of priority tests, and a laboratory utilization strategy using regional and specialized laboratories.」
We continue sales initiatives targeting the hospital and clinic markets, large facilities and existing users. - FY2018-Q1RaisedAnnual report
「In the clinical testing business, we strengthened coordination between our operating sites and headquarters, sought to develop the hospital and clinic markets, and expanded our business through proposal-based sales using the FMS/branch laboratory model for large facilities, in-depth sales to existing users, including the expansion of priority tests, and a laboratory utilization strategy using regional and specialized laboratories.」
In addition to the traditional clinic market, the hospital market was explicitly identified, broadening the target markets for development. - FY2017RestatedAnnual report
「In the clinical testing business, we continued to strengthen coordination between our operating sites and headquarters and develop the clinic market, while pursuing proposal-based sales to large facilities, in-depth sales to existing users, including the expansion of priority tests, and detailed profitability management for each business partner.」
We continue sales initiatives targeting the clinic market, large facilities and existing users, as well as profitability management by business partner. - FY2017-Q3RestatedAnnual report
「In the clinical testing business, we continued to strengthen coordination between our operating sites and headquarters and develop the clinic market, while pursuing proposal-based sales to large facilities using the FMS/branch laboratory model, which involves leasing testing equipment and systems, providing operational guidance and undertaking the operation of in-house laboratories, as well as in-depth sales to existing users, including the expansion of priority tests. We also advanced detailed profitability management for each business partner.」
We continue sales initiatives targeting the clinic market, large facilities and existing users, as well as profitability management by business partner. - FY2017-Q2RestatedAnnual report
「In the clinical testing business, we have strengthened coordination between our laboratories and headquarters, sought to develop the clinic market, pursued solution-based sales to large facilities using the FMS/branch laboratory model (leasing testing equipment and systems, providing operational guidance, and outsourcing the operation of in-house laboratories), conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and advanced detailed profitability management for each business partner.」
We continue sales initiatives targeting the clinic market, large facilities and existing users, while also expanding sales of priority tests. - FY2017-Q1RestatedAnnual report
「In the clinical testing business, we strengthened coordination between our operating sites and headquarters, sought to develop the clinic market, and pursued proposal-based sales to large facilities using the FMS/branch laboratory model, which involves leasing testing equipment and systems, providing operational guidance and undertaking the operation of in-house laboratories, as well as in-depth sales to existing users, including the expansion of priority tests.」
The company continues sales initiatives targeting clinics, large facilities and existing users. - FY2016First statedAnnual report
「We continued to strengthen our development of the clinic market, while pursuing proposal-based sales to large facilities using the FMS/branch laboratory model, which involves leasing testing equipment and systems, providing operational guidance and undertaking the operation of in-house laboratories, as well as in-depth sales to existing users.」
The sales approaches described target multiple customer segments: clinics, large facilities and existing customers.